A detailed history of Ayrton Capital LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Ayrton Capital LLC holds 92,087 shares of PMCB stock, worth $147,339. This represents 7.31% of its overall portfolio holdings.

Number of Shares
92,087
Previous 276,992 66.75%
Holding current value
$147,339
Previous $792,000 75.63%
% of portfolio
7.31%
Previous 26.3%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$2.09 - $2.89 $386,451 - $534,375
-184,905 Reduced 66.75%
92,087 $193,000
Q2 2023

Aug 14, 2023

SELL
$2.74 - $3.18 $2.06 Million - $2.4 Million
-753,538 Reduced 73.12%
276,992 $792,000
Q1 2023

May 12, 2023

SELL
$2.83 - $3.03 $7,358 - $7,877
-2,600 Reduced 0.25%
1,030,530 $3 Million
Q3 2022

Nov 09, 2022

BUY
$2.24 - $2.85 $1.97 Million - $2.51 Million
880,000 Added 574.68%
1,033,130 $2.48 Million
Q4 2021

Feb 11, 2022

BUY
$2.4 - $3.19 $367,512 - $488,484
153,130 New
153,130 $383,000

Others Institutions Holding PMCB

About PharmaCyte Biotech, Inc.


  • Ticker PMCB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,750,100
  • Market Cap $33.2M
  • Description
  • PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...
More about PMCB
Track This Portfolio

Track Ayrton Capital LLC Portfolio

Follow Ayrton Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ayrton Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ayrton Capital LLC with notifications on news.